| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gil Zalsman, Amos Frisch, Shaul Lev-Ran, Andrés Martin, Elena Michaelovsky, Daniela Bensason, Doron Gothelf, Eitan Nahshoni, Samuel Tyano, Abraham Weizma. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 13. issue 3. 2003-07-11. PMID:12729944. |
studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between drd4 exon iii repeat alleles and the response to risperidone. |
2003-07-11 |
2023-08-12 |
Not clear |
| J Bobes, M P Garc A-Portilla, J Rejas, G Hern Ndez, M Garcia-Garcia, F Rico-Villademoros, A Porra. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. Journal of sex & marital therapy. vol 29. issue 2. 2003-07-08. PMID:12623765. |
frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the eire study. |
2003-07-08 |
2023-08-12 |
Not clear |
| J Bobes, M P Garc A-Portilla, J Rejas, G Hern Ndez, M Garcia-Garcia, F Rico-Villademoros, A Porra. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. Journal of sex & marital therapy. vol 29. issue 2. 2003-07-08. PMID:12623765. |
the aim of this cross-sectional study, the estudio de investigaci n de resultados en esquizofrenia (outcomes research study in schizophrenia; eire study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. |
2003-07-08 |
2023-08-12 |
Not clear |
| J Bobes, M P Garc A-Portilla, J Rejas, G Hern Ndez, M Garcia-Garcia, F Rico-Villademoros, A Porra. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. Journal of sex & marital therapy. vol 29. issue 2. 2003-07-08. PMID:12623765. |
we recruited outpatients diagnosed with schizophrenia according to diagnostic and statistical manual of mental disorders (dsm-iv; american psychiatric association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. |
2003-07-08 |
2023-08-12 |
Not clear |
| Blanka Kores Plesnicar, Bojan Zalar, Martina Tomori, Ivan Krajn. Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. Wiener klinische Wochenschrift. vol 115. issue 1-2. 2003-07-08. PMID:12658913. |
the aim of the present study was to establish whether any changes occur in simple reaction time during treatment with risperidone or olanzapine in in-patients suffering a relapse of schizophrenia. |
2003-07-08 |
2023-08-12 |
Not clear |
| Wai-Kwong Tang, Gabor S Ungvar. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 3. 2003-06-23. PMID:12691772. |
there is a lack of controlled trials examining the effectiveness of electroconvulsive therapy (ect) combined with olanzapine or risperidone in treatment-resistant schizophrenia (trs). |
2003-06-23 |
2023-08-12 |
human |
| C W Ritchie, E Chiu, S Harrigan, K Hall, A Hassett, S Macfarlane, M Mastwyk, D W O'Connor, J Opie, D Ame. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. International journal of geriatric psychiatry. vol 18. issue 5. 2003-06-13. PMID:12766921. |
the impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. |
2003-06-13 |
2023-08-12 |
Not clear |
| Alina Borkowska, Janusz Rybakowsk. [Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia]. Psychiatria polska. vol 36. issue 6 Suppl. 2003-06-05. PMID:12647443. |
[factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia]. |
2003-06-05 |
2023-08-12 |
Not clear |
| Alina Borkowska, Janusz Rybakowsk. [Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia]. Psychiatria polska. vol 36. issue 6 Suppl. 2003-06-05. PMID:12647443. |
the aim of the study was to assess the impact of some clinical factors such as family history of psychiatric illness, obstetric complications and duration of the illness on the effect of treatment with risperidone on psychopathological symptoms and deficits of working memory in patients with schizophrenia. |
2003-06-05 |
2023-08-12 |
Not clear |
| Pierre Lalond. Evaluating antipsychotic medications: predictors of clinical effectiveness. Report of an expert review panel on efficacy and effectiveness. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 48. issue 3 Suppl 1. 2003-05-23. PMID:12728783. |
over the course of the last decade, atypical antipsychotic medications (olanzapine, quetiapine, and risperidone) have become first-line choices for acute and maintenance treatment for schizophrenia. |
2003-05-23 |
2023-08-12 |
Not clear |
| D M Taylo. Aripiprazole: a review of its pharmacology and clinical use. International journal of clinical practice. vol 57. issue 1. 2003-05-19. PMID:12587943. |
once-daily aripiprazole 15-30 mg is as effective as haloperidol 10 mg/day and risperidone 6 mg/day in short-term treatment of schizophrenia and more effective than haloperidol 7-10 mg/day in maintenance of response in chronic schizophrenia. |
2003-05-19 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Kazuo Mihara, Tsuyoshi Kondo, Takahiro Kubota, Tatsuji Iga, Yutaka Takarada, Ronald De Vries, Sunao Kaneko, Tomonori Tateish. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. Journal of clinical pharmacology. vol 43. issue 2. 2003-05-13. PMID:12616663. |
effects of cyp2d6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in japanese patients with schizophrenia. |
2003-05-13 |
2023-08-12 |
human |
| Hsien-Yuan Lane, Yue-Cune Chang, Yiao-Cheung Cheng, Guang-Chyi Liu, Xing-Ru Lin, Wen-Ho Chan. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. The Journal of clinical psychiatry. vol 64. issue 3. 2003-05-09. PMID:12716274. |
effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. |
2003-05-09 |
2023-08-12 |
Not clear |
| V Molina, J D Gispert, S Reig, J Sanz, J Pascau, A Santos, T Palomo, M Desc. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505132. |
cerebral metabolism and risperidone treatment in schizophrenia. |
2003-04-24 |
2023-08-12 |
Not clear |
| V Molina, J D Gispert, S Reig, J Sanz, J Pascau, A Santos, T Palomo, M Desc. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505132. |
this paper compares the metabolic changes associated with risperidone treatment in schizophrenia to those induced by haloperidol, as a representative typical neuroleptic. |
2003-04-24 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. |
2003-04-24 |
2023-08-12 |
Not clear |
| Alan I Green, Ellen S Burgess, Ree Dawson, Suzannah V Zimmet, Rael D Strou. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia research. vol 60. issue 1. 2003-04-24. PMID:12505141. |
we describe a retrospective study of the effects of the novel antipsychotics risperidone (risp) and clozapine on alcohol and cannabis use in patients with schizophrenia or schizoaffective disorder and comorbid alcohol and/or cannabis use disorder. |
2003-04-24 |
2023-08-12 |
Not clear |
| L Conlon, T J Fahy, R OToole, J Gilligan, P Prescot. Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. European psychiatry : the journal of the Association of European Psychiatrists. vol 17. issue 8. 2003-04-23. PMID:12504262. |
risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. |
2003-04-23 |
2023-08-12 |
Not clear |
| Adekola O Alao, Kamna Malhotra, Mantosh J Dewa. Comparing the side effect profile of the atypical antipsychotics. West African journal of medicine. vol 21. issue 4. 2003-04-22. PMID:12665274. |
post clozapine, the food and drug administration (fda) has approved the use of four newer atypical antipsychotics; risperidone, olanzapine, quetiapine and ziprasidone for the treatment of schizophrenia. |
2003-04-22 |
2023-08-12 |
Not clear |
| Chia-Yih Liu, Nan-Ying Chiu, Ching-Kuan Wu, Lo-Ming Yuan, Mei-Chun Hsiao, Oscar Lia. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. International clinical psychopharmacology. vol 18. issue 1. 2003-04-15. PMID:12490775. |
optimal dose of risperidone and olanzapine for patients with schizophrenia in taiwan. |
2003-04-15 |
2023-08-12 |
Not clear |